Alpelisib (BYL719), the first oral isoform-selective PI3K inhibitor targeting the p110α isoform of wild-type PI3Kα, has received FDA and EMA approval for metastatic breast cancer treatment (148). Here, PIK3CA is linked to breast carcinoma.